Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
Elisa Marilly, Judith Cottin, Natalia Cabrera, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 2000-2010
Open Access | Times Cited: 63

Showing 26-50 of 63 citing articles:

EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure
Natalie Kreitzer, Nancy M. Albert, Alpesh Amin, et al.
Cardiorenal Medicine (2025), pp. 1-33
Open Access
SGLT-2 inhibitors and diabetic ketoacidosis
F. Agozzino, Teresa Falco, Antonio Villa
Internal and Emergency Medicine (2025)
Closed Access
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study
Muhammad Abdul‐Ghani, Curtiss Puckett, Siham Abdelgani, et al.
BMJ Open Diabetes Research & Care (2025) Vol. 13, Iss. 2, pp. e004981-e004981
Open Access
Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
Preethika Ekanayake, Sunder Mudaliar
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2022) Vol. 17, Iss. 2, pp. 102702-102702
Closed Access | Times Cited: 16
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: a retrospective analysis
Hyeon A Kim, Joo Yeon Kim, Young Hwan Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Are We Ready for Expanding the Use of Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?
Paschalis Karakasis, Dimitrios Patoulias, George Giannakoulas, et al.
Journal of Cardiovascular Pharmacology (2024) Vol. 84, Iss. 1, pp. 26-28
Open Access | Times Cited: 3
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Loredana N. Ionică, Darius G. Buriman, Adina V. Lința, et al.
Molecular and Cellular Biochemistry (2024)
Open Access | Times Cited: 3
Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Angela Duvalyan, Ricardo M. La Hoz, Darren K. McGuire, et al.
Journal of Cardiac Failure (2024) Vol. 30, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 2
How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
Zahir Kanjee, Florence M. Brown, Zachary Taxin, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8, pp. 1106-1117
Closed Access | Times Cited: 2
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
André Scheen
Diabetes & Metabolism (2024), pp. 101594-101594
Closed Access | Times Cited: 2
Mumefural prevents insulin resistance and amyloid-beta accumulation in the brain by improving lowered interstitial fluid pH in type 2 diabetes mellitus
Shigekuni Hosogi, Atsukazu Kuwahara, Yuko Kuwahara, et al.
Biomedical Research (2023) Vol. 44, Iss. 1, pp. 17-29
Open Access | Times Cited: 5
Treatment of type 2 diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Deleted Journal (2024) Vol. 20, Iss. 2, pp. 212-260
Closed Access | Times Cited: 1
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, et al.
Experimental and Clinical Endocrinology & Diabetes (2024) Vol. 132, Iss. 07, pp. 340-388
Open Access | Times Cited: 1
Common mistakes concerning diabetes management in daily clinical practice
Konstantinos Makrilakis, Eleftheria Papachristoforou
Primary care diabetes (2024)
Closed Access | Times Cited: 1
The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients
Peter Biesenbach, Laurits Juhl Heinsen, Katrine Schultz Overgaard, et al.
Cardiovascular Therapeutics (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 3
Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023
Brady Wisniewski, Eric L. Smith, Jasmeen Kaur, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 30, Iss. 1, pp. 34-42
Open Access | Times Cited: 3
Sodium-glucose cotransporter-2 inhibitors: a swinging pendulum in the treatment of acute myocardial infarction
Buena Aziri, Edin Begić, Bojan Stanetić, et al.
Minerva Cardiology and Angiology (2023) Vol. 72, Iss. 3
Closed Access | Times Cited: 2
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Sohee Park, Han Eol Jeong, Sungho Bea, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3248-3258
Open Access | Times Cited: 2
The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review
Rachel Porth, Karina Oelerich, Mala S. Sivanandy
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1056-1056
Open Access
Insulin Delivery Hardware: Pumps and Pens
Rayhan A. Lal, Lalantha Leelarathna
Diabetes Technology & Therapeutics (2024) Vol. 26, Iss. S1, pp. S-44
Closed Access
Understanding The Role of SGLT2 Inhibitors in Cardiovascular Risk Reduction for Type 2 Diabetes Patients-A Literature Review
Jorge Eduardo Arteaga Molina, Ney Asdrubal Macias Valdez, Diego Alberto Vargas Corredor, et al.
International Journal of Medical Science and Clinical Research Studies (2024) Vol. 04, Iss. 03
Open Access
Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
Yao Wang, Chengxia Jiang, Xiaolin Dong, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2774-2786
Closed Access
New diabetic agents providing a glucose feast for urinary yeast – what to do?
Gordon Chen, Andrew A. Mahony, Janelle Brennan, et al.
BJU International (2024) Vol. 134, Iss. S2, pp. 6-8
Open Access

Scroll to top